Corcept Therapeutics Incorporated

Financials

Overview Finanzbericht Statistics Dividends

Cash from operating activities 151.97 M167.89 M120.32 M127.04 M198.07 M142 M 142 M Cash from investing activities 119.26 M136.13 M114.33 M90.91 M177.6 M69.76 M 69.76 M Cash from financing activities 12.21 M302.59 M17.28 M148.72 M28.35 M-220.37 M 157.93 M Free cash flow 150.73 M167.42 M119.91 M126.9 M195.9 M141.78 M 141.78 M

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated

Nachrichten

Corcept's Q4 Earnings and Revenues Fall Short of Estimates

H.C. Wainwright senkt Kursziel für Corcept Therapeutics wegen Lieferproblemen auf 60 $/n

H.C. Wainwright cuts Corcept Therapeutics stock price target to $60 on supply issues

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript

Corcept Therapeutics enttäuscht mit Quartalszahlen und schwachem Ausblick

Corcept Therapeutics falls on revenue miss, weak guidance

Corcept earnings missed by $0.05, revenue fell short of estimates

H.C. Wainwright cuts Corcept Therapeutics price target on patent ruling

Corcept Therapeutics: The Bad News Is Priced In, The Ovarian Cancer Upside Is Not (CORT)

Lam Research, Goldman Sachs among market cap stock movers on Thursday

Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva - TipRanks.com